Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy
TOKYO--(BUSINESS WIRE)-- #Asia--Cellusion Inc., a regenerative medicine startup aiming to solve the global Corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment (PJ code: CLS001), today announced it has completed a 1.1 billion yen fundraising round led by existing investors DBJ Capital, Keio Innovation Initiative, and SMBC Venture Capital and new in